Fulfilling the Promise of Real-World Evidence

Qin Ye, Abhay Jha and Aaron Mitchell

> Download

Availability of real-world data and generating evidence from it has dramatically changed how life sciences have been showcasing the value of a therapy. Regulatory bodies, payers and providers have begun to pressure pharmaceutical companies to adopt real-world evidence (RWE) as it better illustrates therapeutic value. Some companies have taken initial steps towards building RWE capabilities. However, establishing and driving a full-fledged, successful RWE capability can be challenging.

Read this article to learn:

  • What are the different challenges that life sciences companies face while establishing RWE capability
  • Five key steps to developing a successful RWE capability
  • Instances of life science companies that have already achieved success with RWE

About the Expert

Qin Ye: Qin is the Global Real World Evidence (RWE) lead for ZS. As a trained physician, informatician and data scientist, Qin has over 15 years of health informatics and data analytics experiences with various provider and pharmaceutical organizations. In his current role, Qin leads the development of our RWE team, oversees the development of our RWE capabilities, and works directly with clients on RWE programs across clinical, HEOR, medical, and commercial functions.

Aaron Mitchell: Aaron is a managing principal and the global lead for ZS’s R&D excellence practice. Aaron partners with clients to strengthen the value of their pipelines, optimize the execution of clinical trials, drive effective use of real-world evidence and improve medical and scientific engagement.

Abhay Jha: Abhay is the technology lead for ZS’s R&D Excellence Practice and manages the assimilation of technology and functional capabilities in pharmaceutical R&D. An Engineer by education, Abhay advises life sciences companies on the application of existing and advanced technology to solve business challenges in real-world evidence, clinical development and drug safety.